Start with chronic myelogenous leukemia, then reuse UniProt P07948 as the stable protein anchor across project notes and exports.
CHEMBL3905 Target Snapshot
Tyrosine-protein kinase Lyn · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Tyrosine-protein kinase Lyn shows late clinical disease relevance led by chronic myelogenous leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P07948. Start with chronic myelogenous leukemia, then reuse UniProt P07948 as the stable protein anchor across project notes and exports.
Tyrosine-protein kinase Lyn shows late clinical disease relevance led by chronic myelogenous leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with chronic myelogenous leukemia because it currently carries late clinical support. Linked drugs include BOSUTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyTyrosine-protein kinase Lyn
Review this target as Tyrosine-protein kinase Lyn, mapped to UniProt P07948. Sequence length is 512 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Tyrosine-protein kinase Lyn as ChEMBL target CHEMBL3905, mapped to UniProt P07948. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Tyrosine-protein kinase Lyn is the right protein anchor across sources, using UniProt P07948 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic myelogenous leukemia is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Tyrosine-protein kinase Lyn |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P07948 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Tyrosine-protein kinase Lyn |
| UniProt Accession | P07948 |
| Component Type | Protein |
| Sequence Length | 512 aa |
Tyrosine-protein kinase Lyn
How to read this target
Review this target as Tyrosine-protein kinase Lyn, mapped to UniProt P07948. Sequence length is 512 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Tyrosine-protein kinase Lyn shows late clinical disease relevance led by chronic myelogenous leukemia. 5 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with chronic myelogenous leukemia because it currently carries late clinical support. Linked drugs include BOSUTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1171837 | 9.8 | IC50 | 0.16 | Approved |
| CHEMBL475584 | 9.4 | IC50 | 0.4 | Preclinical |
| CHEMBL388978 | 9.32 | IC50 | 0.473 | Preclinical |
| CHEMBL5416410 | 9.24 | Kd | 0.57 | Approved |
| CHEMBL272888 | 9.05 | IC50 | 0.9 | Preclinical |
| CHEMBL249317 | 9.0 | IC50 | 1.0 | Preclinical |
| CHEMBL5416410 | 8.92 | IC50 | 1.2 | Approved |
| CHEMBL3647967 | 8.92 | IC50 | 1.2 | Preclinical |
| CHEMBL508928 | 8.9 | Ki | 1.259 | Preclinical |
| CHEMBL1916879 | 8.81 | IC50 | 1.55 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 798 assays, 499 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 639 | 337 | 6.5 |
| cell-based format | 73 | 119 | 6.6 |
| assay format | 60 | 5 | 6.6 |
| subcellular format | 25 | 37 | 6.4 |
| cell membrane format | 1 | 1 | 8.5 |
ADME — 4 assays, 2 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 3 | 2 | 8.0 |
| cell-based format | 1 | 0 | — |
Functional — 2 assays, 202 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 1 | 201 | 6.9 |
| cell-based format | 1 | 1 | 6.8 |